Prospectus & Target Market Determination
Released
Released
Announcement PDF
PHARMAUST LIMITED
(ACN 094 006 023)
NEW OPTIONS OFFER PROSPECTUS
For the offer of up to 79,224,912 New Options on the basis of 1 New Option for every 1
Lapsed Option held by Eligible Lapsed Option Holders at an issue price of 0.5 cents per
New Option, to raise up to approximately $396,125
This document is a transaction specific prospectus issued in accordance with section 713 of the
Corporations Act. This Prospectus contains important information about the Offer. You should read
the entire document including the Acceptance Form. If after reading this Prospectus you have any
questions about the Offer or this Prospectus, you should speak to your professional adviser.
The Options offered by this Prospectus should be considered highly speculative.
IMPORTANT NOTICE
This Prospectus is dated 21 November 2023 and was lodged with ASIC on that date. Neither ASIC,
ASX nor any of their respective officers take any responsibility for the contents of this Prospectus or
the merits of the investment to which this Prospectus relates.
Certain terms and abbreviations used in this Prospectus have defined meanings, which are
explained in the Glossary. In this Prospectus, the words "we", "our" and "us" refer to the Company.
The words "you" or "your" refer to Shareholders.
No securities will be issued on the basis of this Prospectus later than 13 months after the date of this
Prospectus. Application for quotation of the New Options will be made to ASX within 7 days after
the date of this Prospectus.
We are an ASX listed company whose securities are granted official quotation by ASX. In preparing
this Prospectus, regard has been had to the fact that we are a disclosing entity for the purposes of
the Corporations Act and that certain matters may reasonably be expected to be known to investors
and professional advisers who investors may consult.
No person is authorised to give any information or to make any representations in connection with
this Offer that is not contained in this Prospectus. Any information or representation that is not
contained in this Prospectus may not be relied upon as having been authorised by the Directors or
by us.
Restrictions on distribution
The Offer is made in Australia and New Zealand only. This Prospectus does not constitute an offer
in any overseas jurisdiction where it would be unlawful to make the Offer. You must ensure
compliance with all laws of any country relevant to your Application. We will take the return of a duly
completed Acceptance Form as a representation by you that there has been no breach of any laws
and that you are an Eligible Lapsed Option Holder.
The Corporations Act prohibits any person passing on to another person an application form unless
it is accompanied by or included in a hard copy, or the complete and unaltered electronic version of
this Prospectus. Please contact us if you wish to obtain a hard copy of this Prospectus free of
charge.
A copy of this Prospectus can be downloaded from our website at www.pharmaust.com. If you
access the electronic version of this Prospectus you should ensure that you download and read the
entire Prospectus. The electronic version of this Prospectus is only available to Australian residents.
Target Market Determination
A Target Market Determination (TMD) in respect of the offer of New Options under this Prospectus
has been prepared by the Company and is available on the Company's website at
www.pharmaust.com.
The TMD seeks to offer potential investors with an understanding of the class of investors for which
the offer of New Options has been designed, having regard to the objectives, financial situation and
needs of the target market.
PharmAust Limited
Prospectus
CORPORATE DIRECTORY
DIRECTORS
SOLICITORS
Dr Roger Aston (Non-Executive Chairman)
Mr Robert Bishop (Executive Director)
Mr Sam Wright (Non-Executive Director)
Mr Neville Bassett, AM (Non-Executive Director)
Fairweather Corporate Lawyers
Suite 2, 589 Stirling Highway
Cottesloe, Western Australia, 6011
LEAD MANAGER
CHIEF EXECUTIVE OFFICER
Dr Michael Thurn
COMPANY SECRETARY
Blue Ocean Equities Pty Limited
Level 29 Aurora Place
88 Phillip Street
Sydney NSW 2000
AFSL No. 412765
Mr Sam Wright
SHARE REGISTRY *
REGISTERED OFFICE
Suite 116, 1 Kyle Way
Claremont, Western Australia, 6010
www.pharmaust.com
Computershare Investor Services Pty
Limited
Level 11
172 St George's Terrace
Perth, Western Australia, 6000
ASX Code : PAA
* The name of the Share Registry is included for information purposes only. It has not been
involved in the preparation of any part of this Prospectus and has not consented to being named
in the Prospectus.
PharmAust Limited
Prospectus
TABLE OF CONTENTS
1.
INVESTMENT OVERVIEW ................................................................................................. 1
2.
REASON FOR THE OFFER AND EFFECT ON THE COMPANY ....................................... 6
2.1
Background ......................................................................................................................... 6
2.2
Use of funds ........................................................................................................................ 6
2.3
Effect on shareholders’ equity and cash reserves ................................................................ 6
2.4
Effect on capital structure .................................................................................................... 6
2.5
Pro-forma balance sheet ..................................................................................................... 7
2.6
Potential effect on control of the Company .......................................................................... 8
3.
RISK FACTORS.................................................................................................................. 9
3.1
Introduction.......................................................................................................................... 9
3.2
Company and Industry Risks ............................................................................................... 9
3.3
General Investment Risks .................................................................................................. 12
4.
DETAILS OF THE OFFER ................................................................................................ 13
4.1
The Offer ........................................................................................................................... 13
4.2
How to accept the Offer ..................................................................................................... 13
4.3
Issue and quotation ........................................................................................................... 15
4.4
Lead Manager to place Shortfall and Corporate Advisor Agreement.................................. 15
4.5
Shortfall ............................................................................................................................. 16
5.
RIGHTS ATTACHING TO NEW OPTIONS AND UNDERLYING SECURITIES ................ 17
5.1
Rights attaching to New Options........................................................................................ 17
5.2
Rights attaching to underlying securities (Shares) ............................................................. 18
6.
ADDITIONAL INFORMATION .......................................................................................... 20
6.1
Transaction specific prospectus and continuous disclosure obligations ............................. 20
6.2
Market price of Shares....................................................................................................... 21
6.3
Directors’ Interests............................................................................................................. 22
6.4
Interests of experts and advisers ....................................................................................... 23
6.5
Expenses of the Offer ........................................................................................................ 24
6.6
Consents ........................................................................................................................... 24
7.
DIRECTORS' AUTHORISATION AND CONSENT ........................................................... 25
8.
GLOSSARY ...................................................................................................................... 26
PharmAust Limited
Prospectus
1.
INVESTMENT OVERVIEW
Question
Response
Where to find
more
information
What is the
Offer?
We are offering to issue New Options to Eligible Lapsed Option
Holders.
Section 2.1
Under the Offer, Eligible Lapsed Option Holders may subscribe
for 1 New Option for every 1 Lapsed Option held on the Record
Date.
What is the
Issue Price for
the New
Options?
The Issue Price is 0.5 cents per New Option.
Section 2.1
What are the
terms of the
New Options?
The New Options have an exercise price of 15 cents and an
expiry date of 30 April 2026. The Company will apply for
quotation of the New Options on ASX. The full terms of the New
Options are set out in Section 5.1.
Section 5.1
Who is an
The Offer is made to Eligible Lapsed Option Holders only. An
Eligible Lapsed Eligible Lapsed Option Holder is a Lapsed Option Holder with a
Option Holder? registered address in Australia or New Zealand on the Record
Date.
Section 4.1(a)
How many
New Options
will be issued?
The maximum number of New Options that may be issued under Section 2.1
the Offer is approximately 79,224,912.
What is the
amount that
will be raised
under the
Offer?
The maximum amount that may be raised under the Offer is up
to $396,125 before expenses (representing the issue of
79,224,912 New Options at an Issue price of 0.5 cents per New
Option).
Section 2.1
What will the
funds raised
be used for?
The Offer will raise funds to be used as additional working
capital for the Company and to meet Offer expenses.
Section 2.2
What is the
The effect of the Offer is to:
effect of the
• Increase the number of Options on issue.
Offer on capital
and cash
• Increase our cash reserves by up to approximately $396,125
reserves?
(at Full Subscription and before the expenses of the Offer).
Section 2.3
What are the
key risks of a
further
Section 3
PharmAust Limited
Prospectus
The Offer should be considered highly speculative as the
Company is developing therapeutics for cancer and
neurodegenerative diseases in humans and cancer for pet dogs.
Page 1
Question
Response
investment in
the Company?
Before deciding to subscribe under the Offer, you should
consider the risk factors set out in this Prospectus and our public
announcements. Some of the specific risks relevant to an
investment in the Company are:
Risk Area
PharmAust Limited
Prospectus
Where to find
more
information
Risks
Commercialisation of
key monepantel
product
The Company's future success
depends in part on its ability to
commercialise its key product,
monepantel (MPL) as a therapeutic
including in treating some cancer
and neurodegenerative diseases, in
humans and cancer in pet dogs.
Commercialisation of this and any
other products may be reliant on the
ability of the Company to effectively
collaborate with a larger
pharmaceutical or healthcare
company. No assurances can be
given of the successful development
and commercialisation of products
that are being developed.
Future Funding
The Company is yet to commercialise
its products or generate material
revenue or profits. The Company will
therefore depend on its ability to raise
additional funds. No assurance can
be given that future investor funds as
required will be made available on
acceptable terms (if at all). If the
Company is unable to obtain
additional financing (whether equity or
debt) as is needed, it may be required
to reduce the scope of its operations
and scale back its programs.
Intellectual property
risk
The success of the Company will
depend in part on the Company's
ability to secure and protect rights to
intellectual property and, in particular,
patents (and therefore proprietary
rights) without infringing the
proprietary rights of others. The
Company has intellectual property
rights to the use of MPL including in
the treatment of cancer and
Page 2
Question
Response
Where to find
more
information
neurodegenerative diseases in
humans and cancer in pet dogs. The
strength of patents, even if granted,
involves complex legal and scientific
questions and can be uncertain.
How do I
accept my
New Options
under the
Offer?
Clinical validation and
regulatory risk
The commercialisation and
registration of products being
developed by the Company requires
regulatory approval in various
jurisdictions. Additionally, ethical
body approval may be required.
Although the Company has obtained
approval to date to conduct its trials,
there is inherent uncertainty involved
in obtaining relevant regulatory
approval as the Company progresses
towards commercialisation.
Dependence on key
personnel
The Company’s success depends in
part on the core competencies of the
Directors and management and the
ability of the Company to retain these
key executives. Loss of key
personnel may have an adverse
impact on the Company's
performance, particularly given the
small size of the team.
All Eligible Lapsed Option Holders are entitled to subscribe for
New Options under the Offer. If you wish to make an
Application in respect of your Entitlement, you must make
payment in accordance with instructions on the Acceptance
Form that accompanies this Prospectus.
Section 4.2(a)
You may accept all or part of your Entitlement.
If you do not wish to take up any of your Entitlement, you do not
need to take any action and your Entitlement will lapse.
What will
happen to
Excluded
Lapsed Option
Holders?
The Offer is not extended to Excluded Lapsed Option Holders
(any Lapsed Option Holder whose registered address on the
Record Date is not situated in Australia or New Zealand).
Section 4.2(b)
Is the Offer
underwritten?
The Offer is not underwritten.
Section 4.1(c)
PharmAust Limited
Prospectus
Page 3
Question
Response
Where to find
more
information
What are the
Lead Manager
arrangements
concerning
Shortfall and
how will
Shortfall be
issued?
Any Entitlement not accepted will form part of the Shortfall. The
Offer to issue Shortfall is a separate offer under this Prospectus.
Sections 4.4
and 4.5
Blue Ocean Equities is the Lead Manager.
The Lead Manager has been engaged to place any Shortfall on
a best efforts basis in conjunction with the Directors of the
Company. The Lead Manager will be paid a fee of 6% plus GST
on the funds raised by the placement of any Shortfall by it.
Additionally, under the terms of a corporate advisor agreement,
the Lead Manager will be issued with 3,000,000 Corporate
Advisor Options as a separate offer under this Prospectus and
on the same terms as the New Options.
Shortfall will be allocated and issued by the Lead Manager in
conjunction with the Directors of the Company to parties that are
not related parties of the Company and on the same terms as
being offered to Eligible Lapsed Option Holders under this
Prospectus.
What is the
effect of the
Offer on
control of the
Company?
The New Options have no participating rights or entitlements
until exercised. It is only upon exercise of the New Options and
the issue of Shares that rights such as voting rights arise.
Section 2.6
The effect of the Offer on the capital structure is set out in
Section 2.4. If all the New Options are issued under the Offer
they will represent approximately 17.65% of the enlarged capital
of the Company on a fully diluted basis (assuming all other
Options are exercised) at the date of this Prospectus.
By reason of the above and the Offer being to Lapsed Option
Holders on a pro-rata basis, the Offer should not have a material
effect on the control of the Company.
What are the
key dates of
the Offer?
PharmAust Limited
Prospectus
ASX announcement of Offer
18 October 2023
Lapsed Options lapse/Record Date
31 October 2023
Shareholder approval to Offer
20 November 2023
Prospectus lodged with ASIC and ASX
21 November 2023
Send Prospectus and Acceptance
Forms to Eligible Lapsed Option
Holders
24 November 2023
Opening Date
24 November 2023
Closing Date
8 December 2023
Page 4
Question
Response
Where to find
more
information
Announce results of Offer
15 December 2023
Issue date
15 December 2023
Please note that these dates are subject to change. We reserve
the right, subject to the Corporations Act and the Listing Rules,
to amend the timetable at any time, and in particular, to extend
the Closing Date or to withdraw the Offer without prior notice.
PharmAust Limited
Prospectus
Page 5
2.
REASON FOR THE OFFER AND EFFECT ON THE COMPANY
2.1
Background
The Company is making this Offer which consists of a pro-rata issue of New Options to
Eligible Lapsed Option Holders on the basis of 1 New Option for every 1 Lapsed Option held
by Eligible Lapsed Option Holders on the Record Date at an issue price of 0.5 cents per New
Option ("Offer").
The Offer will raise up to $396,125 before expenses at Full Subscription by the issue of
79,224,912 New Options. The New Options have an exercise price of 15 cents and an expiry
date of 30 April 2026.
The Company will apply for quotation of the New Options on ASX as well as other Options
on the same terms that are on issue or will be issued. See note 2 to section 2.4 below.
2.2
Use of funds
The funds raised by the Offer of up to approximately $396,125 will therefore be used as
additional working capital for the Company and to meet Offer expenses of approximately
$60,000.
2.3
Effect on shareholders’ equity and cash reserves
Assuming that all New Options offered under the Offer are issued, the principal effects of the
Offer on the Company will be to:
(a)
increase the total number of Options on issue by the New Options (see Section 2.4);
and
(b)
increase our cash reserves by approximately $396,125, before taking into account
the expenses of the Offer (see Sections 2.5 and 6.5).
A pro forma statement of financial position, which that contains further information about the
effect of the Offer on the Company, is provided in Section 2.5.
2.4
Effect on capital structure
The effect of the Offer on the Company’s capital structure at the date of the Prospectus and
assuming Full Subscription is shown in the following table:
Shares
Existing Shares
Shares issued under this Offer
Total Shares on issue after completion of
the Offer1
PharmAust Limited
Prospectus
348,778,664
0
348,778,664
Page 6
Options
Existing 10 cent unlisted Options (exercise
price 10 cents expiring 28 February 2026)
2,730,000
Existing 15 cent unlisted Options (exercise
price 15 cents expiring 30 April 2026)2
16,150,006
New Options issued under this Offer (exercise
price 15 cents expiring 30 April 2026)2
Corporate Advisor Options issued under this
Prospectus2 and 3
79,224,912
Total Options on issue after completion of
the Offer
101,104,918
3,000,000
1. The Company also has 2,400,000 Performance Rights on issue to the CEO with
various vesting hurdles and expiry dates as referred to in the ASX announcement of
28 August 2023.
2. The Company will apply for quotation of the New Options plus each of the existing 15
cent unlisted Options and the Corporate Advisor Options as they have the same
exercise price and expiry date and general terms.
3. The Corporate Advisor Options will be issued under the terms of a corporate advisor
agreement between the Company and Lead Manager as summarised in Section 4.4.
2.5
Pro-forma balance sheet
To illustrate the effect of the Offer on the Company, a pro-forma balance sheet has been
prepared based on the audited balance sheet as at 30 June 2023. The pro forma balance
sheet shows the effect of the Offer as if it had been made on 30 June 2023 based on the
following assumptions:
(a)
The issue of 79,224,912 New Options under the Offer at an issue price of 0.5 cents
each to raise $396,125.
(b)
Expenses of the Offer, being approximately $60,000.
Current assets
Cash and cash equivalents
Trade and other receivables
Other current assets
Inventory
Total current assets
30 June 2023
consolidated
audited
$
30 June 2023
consolidated
proforma at Full
Subscription
$
2,705,941
148,233
167,055
0
3,021,229
3,042,066
148,233
167,055
0
3,357,354
Non-current assets
PharmAust Limited
Prospectus
Page 7
Intangible assets
Plant and equipment
Total non-current assets
3,107,476
1,641
3,109,117
3,107,476
1,641
3,109,117
Total assets
6,130,346
6,466,471
Current liabilities
Trade and other payables
Borrowings
Employee benefits
Lease liabilities
Total current liabilities
926,127
0
262,786
158,454
1,347,367
926,127
0
262,786
158,454
1,347,367
3,341
890,503
893,844
3,341
890,503
893,844
Total liabilities
2,241,211
2,241,211
Net assets
3,889,135
4,225,260
57,632,710
2,715,312
(56,458,887)
58,028,835
2,715,312
(56,518,887)
3,889,135
4,225,260
Non-Current Liabilities
Employee benefits
Lease liabilities
Total non-current liabilities
Equity
Issued capital
Reserves
Accumulated losses
Total equity
2.6
Potential effect on control of the Company
The New Options have no participating rights or entitlements until exercised. It is only upon
exercise of the New Options and the issue of Shares that rights such as voting rights arise.
The effect of the Offer on the capital structure is set out in Section 2.4. If all the New Options
are issued under the Offer they will represent approximately 17.65% of the enlarged capital
of the Company on a fully diluted basis (assuming all other Options are exercised) at the date
of this Prospectus.
By reason of the above and the Offer being to Lapsed Option Holders on a pro-rata basis,
the Offer should not have any material effect on the control of the Company.
PharmAust Limited
Prospectus
Page 8
3.
RISK FACTORS
3.1
Introduction
Applicants should be aware that an investment in the Company is highly speculative. The
Company is focused on developing therapeutics including for cancer and neurodegenerative
diseases in humans and cancer for pet dogs.
The activities of the Company are subject to various risks that may impact on the future
performance of the Company. The following is a non-exhaustive list of the risks that may
have a material effect on the financial position and performance of the Company and the
value of its securities. The list is set out under "Company and Industry Risks" and "General
Investment Risks".
3.2
Company and Industry risks
Commercialisation of key monepantel product
The Company's future success depends in part on its ability to commercialise its key product,
monepantel (MPL) as a therapeutic including in treating some cancer and neurodegenerative
diseases in humans and cancer in pet dogs, and any subsequent commercialisation of this
product. Commercialisation of this and any other products may be reliant on the ability of the
Company to effectively collaborate with a larger pharmaceutical or healthcare company. No
assurances can be given of the successful development and commercialisation of products
that are being developed.
Future capital needs and additional funding
The Company is yet to commercialise its products or generate material revenue or profits.
The Company's implementation of its business strategy will depend on its ability to continue
to raise additional funds. The Company's ability to raise further capital (equity or debt) within
an acceptable time, of a sufficient amount and on terms acceptable to it will vary according
to a number of factors, including the success of the development of current products and
industry conditions. No assurance can be given that future funding will be available, or that
it will be available on terms favourable to the Company. If the Company is unable to obtain
additional funding as is needed, it may be required to reduce the scope of its operations and
scale back its programs.
Intellectual property risk
Securing and protecting rights to intellectual property, and in particular to patents, is an
integral part of securing potential product value arising out of the Company's key product.
The Company’s success depends in part, on its ability to obtain patents, protect trade secrets
and operate without infringing third parties’ proprietary rights.
The granting of a patent does not guarantee that the rights of other parties are not infringed
or that competitors will not develop competing intellectual property that circumvents the
patents. In addition, there can be no assurance that any patents that the Company may own
or control or licence now, or in the future, will afford the Company commercially significant
protection of its intellectual property or its projects or have commercial application.
Competition in obtaining, retaining and maintaining protection of intellectual property and the
complex nature of intellectual property rights can also lead to expensive and lengthy disputes
for which there can be no guaranteed outcome.
PharmAust Limited
Prospectus
Page 9
The Company has intellectual property rights to the use of MPL including in the treatment of
cancer and neurodegenerative diseases in humans and cancer in pet dogs.
Clinical validation and regulatory risk
A core component of the Company’s strategy is the commercialisation and registration of
existing and potentially new related products for the treatment of cancer and
neurodegenerative diseases in humans and cancer in pet dogs. Successful trials will be
required in order for the Company to gain regulatory approval and continue on the
commercialisation pathway for its products.
The Company is required to seek regulatory approval to proceed through each phase or
stage of the development of the products. Additionally, ethical body approval may be
required. Due to the inherent uncertainty involved in obtaining such regulatory approval,
there is a risk that the Company's products may not satisfy the requirements for relevant
approval, or that the approval process takes longer than expected and therefore delays
commercialisation.
Dependence on key personnel
The Company's success depends on the core competencies of its Directors and key
management. The expertise and availability of the Company’s scientific staff will be
instrumental in the development of products as well as the success and evaluation of trials.
Loss of key personnel would adversely affect the Company, particularly given the small size
of the team.
Future product development
The Company faces a number of product related risks inherent in the development of its new
drug for clinical markets. These range from clinical trial risk as noted above, an active market
to support the development of new products as well as distribution and manufacturing risk.
The success of projects and product commercialisation depends on partnering with
collaborators interested in the Company’s platform and the appointment and co-operation of
distributors to market and sell products to target segments. Although arrangements can be
confirmed in agreements and undertakings given for the completion of work to be done and
activities to perform, there is a risk that the performance of distributors and the delivery of
contracted outcomes by collaborators will not occur due to a range of unforeseen factors
relating to environment, technology, counterparty risk and market conditions.
Competition in development of products
The Company faces competition in the development of treatment products, which may
include organisations with greater capital resources and expertise. The ability of a current or
new competitor to introduce an improved product may adversely impact on the Company's
financial performance. Such competition and new technologies can have the effect of
rendering costly research and development obsolete, decreasing the financial value of
products or research projects and reducing pricing and profit margins.
Product liability risk
The Company's business of development of treatment products exposes it to potential
product liability claims. The Company may seek to obtain adequate product liability insurance
at the appropriate time in order to minimise its liability to such claims however there can be
PharmAust Limited
Prospectus
Page 10
no assurance that adequate insurance coverage will be available at an acceptable cost. If
the Company is unable to obtain sufficient product liability insurance then claims of this nature
may adversely affect the Company's profitability.
Insurance
The Company may maintain insurance within ranges of coverage that it believes to be
consistent with industry practice and having regard to the nature of activities being conducted
including human trials. However, it is not always possible to cost-effectively insure against
all risks associated with such activities. The Company may decide not to take out insurance
against certain risks as a result of high premiums or for other reasons. Should liabilities arise
on uninsured risks, the Company's business, financial condition and results of operations and
the market price of the Shares may be materially adversely affected.
Legal proceedings
Legal proceedings may arise from time to time in the course of the Company's business. As
at the date of this Prospectus, there are no material legal proceedings affecting the Company
and the Directors are not aware of any legal proceedings pending or threatened against or
affecting the Company.
PharmAust Limited
Prospectus
Page 11
3.3
General Investment Risks
Securities investments and share market conditions
There are risks associated with any securities investment. The trading prices of securities
trade fluctuate in response to a number of factors.
Furthermore, the stock market, and in particular the market for
Share your feedback
Discover